TAK-875, which will no doubt get a catchier name in the next few months, adds to our ever growing collection of options for type 2 diabetes – like GLP-1 agonists and DPP-IV inhibitors. So is it just going to fall by the wayside or be another useful addition?The Lancet reports on a phase 2, randomised double blind placebo controlled trial, comparing this new agent (working on fatty acid stimulated glucose dependent insulin secretion) to glimepiride. Overall, it improved HbA1c, hypoglycaemia was similar to placebo, and adverse events were reasonable – this could become the next new agent.
The final nail in the coffin for sulfonylureas? We’ll soon see. In the meantime, check this out here.
image | Jessica Merz
source | The Lancet